Globus Medical Management

Management Kriterienprüfungen 4/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Dan Scavilla

Geschäftsführender

US$4.6m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	10.2%
Amtszeit als Geschäftsführer	2.4yrs
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	5.4yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	5.3yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Dan Scavilla im Vergleich zu den Einnahmen von Globus Medical verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Jun 30 2024	n/a	n/a	US$41m
Mar 31 2024	n/a	n/a	US$67m
Dec 31 2023	US$5m	US$464k	US$123m
Sep 30 2023	n/a	n/a	US$158m
Jun 30 2023	n/a	n/a	US$204m
Mar 31 2023	n/a	n/a	US$201m
Dec 31 2022	US$4m	US$437k	US$190m
Sep 30 2022	n/a	n/a	US$155m
Jun 30 2022	n/a	n/a	US$155m
Mar 31 2022	n/a	n/a	US$142m
Dec 31 2021	US$2m	US$396k	US$149m
Sep 30 2021	n/a	n/a	US$187m
Jun 30 2021	n/a	n/a	US$184m
Mar 31 2021	n/a	n/a	US$122m
Dec 31 2020	US$2m	US$384k	US$102m
Sep 30 2020	n/a	n/a	US$95m
Jun 30 2020	n/a	n/a	US$89m
Mar 31 2020	n/a	n/a	US$148m
Dec 31 2019	US$2m	US$366k	US$155m
Sep 30 2019	n/a	n/a	US$146m
Jun 30 2019	n/a	n/a	US$143m
Mar 31 2019	n/a	n/a	US$150m
Dec 31 2018	US$2m	US$355k	US$156m
Sep 30 2018	n/a	n/a	US$144m
Jun 30 2018	n/a	n/a	US$134m
Mar 31 2018	n/a	n/a	US$118m
Dec 31 2017	US$1m	US$345k	US$107m

Vergütung im Vergleich zum Markt: DanDie Gesamtvergütung ($USD4.56M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt MX ($USD5.97M).

Entschädigung vs. Einkommen: DanDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Dan Scavilla (59 yo)

2.4yrs

Amtszeit

US$4,564,374

Vergütung

Mr. Daniel T. Scavilla, also known as Dan, serves as President and Chief Executive Officer at Globus Medical, Inc. since April 21, 2022 and serves as its Director since April 2022. He had been Executive Vi...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
David Paul	Co-Founder & Executive Chairman	21.7yrs	US$3.22m	16.44% $ 30.7b
Daniel Scavilla	President	2.4yrs	US$4.56m	keine Daten
Keith Pfeil	CFO & COO	5.1yrs	US$2.06m	0% $ 0
Kelly Huller	Senior VP	5.8yrs	US$1.64m	0% $ 0
Brian Kearns	Senior Vice President of Business Development & Investor Relations	no data	keine Daten	keine Daten

5.4yrs

Durchschnittliche Betriebszugehörigkeit

57yo

Durchschnittliches Alter

Erfahrenes Management: Das Managementteam von GMED * ist erfahren und erfahren (durchschnittliche Amtszeit: 5.1 Jahre).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
David Paul	Co-Founder & Executive Chairman	21.7yrs	US$3.22m	16.44% $ 30.7b
Daniel Scavilla	President	2.4yrs	US$4.56m	keine Daten
Ann Rhoads	Independent Director	13.2yrs	US$490.69k	0.032% $ 59.1m
John DeFord	Independent Director	less than a year	US$276.27k	0.011% $ 21.5m
Stephen Zarrilli	Independent Director	5.3yrs	US$470.69k	0% $ 0
James Tobin	Independent Director	9.1yrs	US$478.19k	0% $ 0
Daniel Wolterman	Independent Director	less than a year	US$278.15k	0.018% $ 33.1m
Robert Douglas	Independent Director	4.8yrs	US$470.69k	0.0015% $ 2.8m
David Davidar	Independent Director	21.5yrs	US$468.19k	0.57% $ 1.1b
Leslie Norwalk	Independent Director	less than a year	US$278.77k	0.012% $ 22.6m
Daniel Lemaitre	Independent Director	13.4yrs	US$478.19k	0% $ 0

5.3yrs

Durchschnittliche Betriebszugehörigkeit

62yo

Durchschnittliches Alter

Erfahrener Vorstand: GMED *Die Vorstandsmitglieder gelten als erfahren (5 Jahre durchschnittliche Amtszeit).

Globus Medical Management

Management Kriterienprüfungen 4/4

Wichtige Informationen

Jüngste Management Updates

Independent Director recently sold Mex$12m worth of stock

Globus Medical, Inc., Annual General Meeting, Jun 05, 2024

Globus Medical Promotes Keith Pfeil to Chief Operating Officer

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

Globus Medical, Inc. Launches ADIRA™? XLIF™? Plate System

Globus Medical, Inc. Revises Earnings Guidance for the Year 2024

Globus Medical, Inc. Receives FDA 510(k) Clearance for Excelsiusflex™? and ACTIFY™? 3D Total Knee System

Globus Medical, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Globus Medical, Inc.(NYSE:GMED) dropped from Russell 1000 Value-Defensive Index

Independent Director recently sold Mex$12m worth of stock

First quarter 2024 earnings released: US$0.053 loss per share (vs US$0.49 profit in 1Q 2023)

Globus Medical, Inc. Updates Earnings Guidance for the Full Year 2024

Globus Medical, Inc., Annual General Meeting, Jun 05, 2024

Globus Medical, Inc. to Report Q1, 2024 Results on May 07, 2024

Globus Medical, Inc. Reaffirms Revenue Guidance for the Full Year 2024

Globus Medical Promotes Keith Pfeil to Chief Operating Officer

Globus Medical, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Globus Medical, Inc. Revises Earnings Guidance for the Year 2023

Globus Medical, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Globus Medical, Inc. (NYSE:GMED) completed the acquisition of NuVasive, Inc. (NasdaqGS:NUVA) from BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc., Thrivent Financial for Lutherans and others.

Globus Medical, Inc. Updates Earnings Guidance for the Year 2023

Globus Medical, Inc. Announces Launch of the Marvel(Tm) Growing Rod System

Globus Medical, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Globus Medical, Inc.(NYSE:GMED) dropped from Russell 1000 Growth-Defensive Index

Insufficient new directors

Globus Medical, Inc. Provides Earnings Guidance for the Full Year 2023

Insufficient new directors

Full year 2022 earnings released: EPS: US$1.89 (vs US$1.48 in FY 2021)

Globus Medical, Inc. (NYSE:GMED) entered into a definitive agreement to acquire NuVasive, Inc. (NasdaqGS:NUVA) for $3.1 billion.

Globus Medical, Inc. to Report Q4, 2022 Results on Feb 21, 2023

Insufficient new directors

Globus Medical, Inc. Reaffirms Net Sales Guidance for the Year 2022

Globus Medical, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Globus Medical, Inc. Reaffirms Sales Guidance for the Full Year 2022

Globus Medical, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Globus Medical, Inc. Announces First Surgeries Using Excelsius3D™

Globus Medical, Inc., Annual General Meeting, Jun 02, 2022

Globus Medical, Inc. to Report Q1, 2022 Results on May 10, 2022

Globus Medical, Inc. Provides Net Sales Guidance for the Full Year 2022

Globus Medical, Inc. to Report Q4, 2021 Results on Feb 17, 2022

Globus Medical, Inc. Announces First ExcelsiusGPS® Cranial Surgery

Globus Medical, Inc. Raises Earnings Guidance for the Full Year 2021

Globus Medical Announces Completion of 20,000 Procedures Utilizing ExcelsiusGPS®

First quarter 2021 earnings released: EPS US$0.45 (vs US$0.26 in 1Q 2020)

Globus Medical, Inc. Raises Earnings Guidance for the Full Year 2021

Full year 2020 earnings released

Revenue beats expectations

Globus Medical, Inc. to Report Q4, 2020 Results on Feb 17, 2021

Globus Medical, Inc.(NYSE:GMED) dropped from Russell 2000 Defensive Index

Globus Medical, Inc. Wins Group Purchasing Agreement with Premier

Globus Medical, Inc. to Report Q3, 2020 Results on Oct 28, 2020

Northwest Specialty Hospital Partners with Globus Medical, Inc to Implement the First Fully Navigated Spinal Surgery for Minimally Invasive Interbody Spine Fusion Procedures

Globus Medical, Inc. (NYSE:GMED) acquired Synoste Oy for $33.3 million.

Globus Medical, Inc. Withdrew Previously Announce Full Year 2020 Guidance

Earnings released

Globus Medical, Inc. to Report Q2, 2020 Results on Aug 05, 2020

Globus Medical, Inc.(NYSE:GMED) dropped from Russell 2000 Defensive Index

Globus Medical, Inc.(NYSE:GMED) dropped from Russell 2500 Growth Index

Globus Medical, Inc.(NYSE:GMED) dropped from Russell 2000 Index

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter